Filtrer vos résultats
- 2
- 1
- 1
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
triés par
|
|
Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancerAnnals of Oncology, 2017, 28 (10), pp.2436 - 2442. ⟨10.1093/annonc/mdx351⟩
Article dans une revue
hal-01705297v1
|
||
|
PO-0702: Phase I trial evaluating panitumumab in combination with chemoradiotherapy for anal cancersESTRO 36, May 2017, Vienne, Austria. , Radiotherapy and Oncology, 123 (Supplement 1), pp.S367 - S368, 2017, ESTRO 36, May 5-9, 2017, Vienna, Austria. ⟨10.1016/S0167-8140(17)31139-8⟩
Poster de conférence
hal-01685153v1
|